9999999997-17-005944.txt : 20170504 9999999997-17-005944.hdr.sgml : 20170504 20170504140740 ACCESSION NUMBER: 9999999997-17-005944 CONFORMED SUBMISSION TYPE: CT ORDER PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20170504 DATE AS OF CHANGE: 20170504 20170504 20170504 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vanda Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001347178 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 030491827 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: CT ORDER SEC ACT: 1934 Act SEC FILE NUMBER: 001-34186 FILM NUMBER: 17813291 BUSINESS ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 BUSINESS PHONE: 202-734-3400 MAIL ADDRESS: STREET 1: 2200 PENNSYLVANIA AVE NW STREET 2: SUITE 300E CITY: WASHINGTON STATE: DC ZIP: 20037 CT ORDER 1 filename1.pdf begin 644 filename1.pdf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